New Research Highlights Benefits of Metformin in Reducing Cardiovascular Disease and Cancer Risk

Strategic Insights -

Researchers have uncovered new benefits of metformin in reducing the risk of cardiovascular disease and cancer in patients with type 2 diabetes, according to a study published in the Lancet. The study, based on data from the UK Prospective Diabetes Study (UKPDS), showed that metformin reduced diabetes-related deaths by 42% and all-cause mortality by 36% compared to those who did not receive metformin. Additionally, research presented at the European Association for the Study of Diabetes (EASD) conference suggests that metformin may also reduce cancer risk in patients with type 2 diabetes.

Key Takeaways:

  • Metformin is recommended as the first-line treatment for type 2 diabetes due to its benefits in reducing cardiovascular disease and cancer risk.
  • The UK Prospective Diabetes Study (UKPDS) found that metformin reduced diabetes-related deaths by 42% and all-cause mortality by 36%.
  • Research presented at EASD conference suggests that metformin may reduce cancer risk in patients with type 2 diabetes by 21% compared to sulfonylurea or insulin therapy.
  • A case-control study in Scotland involving 11,876 individuals found that metformin users had a lower risk of cancer-related mortality compared to sulfonylurea users.
  • Metformin's anti-tumor effects are supported by a population-based cohort study that found a 23% reduction in cancer risk in patients who used metformin compared to those who used sulfonylurea or insulin.
  • The study's findings have important implications for prevention and management of cancer in patients with type 2 diabetes.

Statistics:

  • 42% reduction in diabetes-related deaths among patients who received metformin compared to those who did not (UKPDS).
  • 36% reduction in all-cause mortality among patients who received metformin compared to those who did not (UKPDS).
  • 21% reduction in cancer risk among metformin users compared to sulfonylurea or insulin users (EASD conference).
  • 23% reduction in cancer risk among metformin users compared to sulfonylurea or insulin users (population-based cohort study).
  • 28% reduction in major adverse events among patients with proven CHD who received metformin compared to sulfonylurea/insulin users (PRESTO trial).

Sources:

  • International Diabetes Federation (2005). Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Available from
  • UK Prospective Diabetes Study Group (1998). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 352(9131), 854-865.
  • Kao, J., Tobis, J., McClelland, R. L., Heaton, M. R., Davis, B. R., Holmes, D. R., & Currier, J. W. (2004). Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. American Journal of Cardiology, 93(12), 1347-1350.
  • Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005). Metformin and reduced risk of cancer in diabetic patients. British Medical Journal, 330(7493), 1304-1305.
  • Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2005). Increased cancer related mortality for patients with type 2 diabetes who use sulfonylurea or exogenous insulin compared to metformin. Diabetes, 54(Suppl 1), A128.